Drug resistance in leprosy

Japanese Journal of Infectious Diseases

Volumn 63, Issue 1, 2010, Pages 1-7

  Matsuoka, Masanori ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; GLUCOSULFONE; MINOCYCLINE; OFLOXACIN; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; CHEMOTHERAPY; CODON; DISEASE CONTROL; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; FOOT PAD; GENE MUTATION; GENE SEQUENCE; HISTORY OF MEDICINE; HUMAN; LEPROSY; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM LEPRAE; NONHUMAN; REVIEW; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; LEPROSY; MICE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM LEPRAE;

EID: 76649138947     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Study Group for Epidemiological Surveillance (2009): Newly detected case of leprosy in Japan during 2008. Jpn. J. Lepr., 78, 315-316 (in Japanese).
2. World Health Organization (2009): Global leprosy situation. Wkly. Epidemiol. Rec., 84, 333-340.
3. Ridley, D.S. and Jopling, W.H. (1966): Classification of leprosy according to immunity: a five-group system. Int. J. Lepr. Other Mycobact. Dis., 34, 255-273.
4. WHO Study Group (1982): Chemotherapy of leprosy for control programs. WHO Tech. Rep. Ser., 675.
5. WHO Expert Committee on Leprosy (1998): Seventh Report WHO Technical report series, 874.
6. Wolcott, R.R. and Ross, H. (1953): Exacerbation of leprosy during present day treatment. Int. J. Lepr., 21, 437-440.
7. dela Cruz, E., Cellona, R.V., Balagon, M.V.F., et al. (1996): Primary dapsone resistance in Cebu, the Philippines; cause for concern. Int. J. Lepr. Other Mycobact. Dis., 64, 253-256.
8. Cambau, E., Perani, E., Guillemin, I., et al. (1997): Multidrug resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet, 349, 103-104.
9. Matsuoka, M., Kashiwabara,Y. and Namisato, Y. (2000): A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin, and sparfloxacin. Int. J. Lepr. Other Mycobact. Dis., 68, 452-455.
10. Matsuoka, M., Kashiwabara, Y., Zhang, L.F., et al. (2003): A second case of multidrug-resistant Mycobacterium leprae isolated from a Japanese patient with relapsed lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis., 71, 240-243.
11. Gelber, R.H. and Gibsone, J. (1979): The killing potential of various aminoglicoside antibiotics for M. leprae. Int. J. Lepr. Other Mycobact. Dis., 47, 684-685.
12. Gelber, R.H., Siu, P., Tsang, M., et al. (1991): Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob. Agents Chemother., 35, 760-763.
13. Gelber, R.H., Iranmanesh, A., Murry, L.P., et al. (1992): Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice. Antimicrob. Agents Chemother., 36, 2544-2547.
14. Chan, G.P., Garcia-Ignacio, B.Y., Chavez, V.E., et al. (1994): Clinical trial of saparfloxacin for lepromatous leprosy. Antimicrob. Agents Chemother., 38, 61-65.
15. Gelber, R.H., Pardillo, F.E. and Borgos, J. (2006): Powerful bacterial activity observed in the first clinical trial of moxifloxacian in leprosy. Abstr. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 43, 371.
16. Shepard, C.C. (1969): Minimal effective dosage in mice of clofazimine (B663) and of ethionamide against Mycobacterium leprae. Proc. Soc. Exp. Biol. Med., 132, 120-124.
17. Jacobson, R.R. (1994): Treatment of leprosy. p.317-349. In Hastings, R.H. (ed.), Leprosy. Churchill Livingston, Edinburgh.
18. Faget, G.H., Pogge, R.C., Johansen, F.A., et al. (1943): The promin treatment of leprosy: a progress report. Public Health Rep., 58, 1792-1741.
19. Kai, M., Matsuoka, M., Nakata, N., et al. (1999): Diaminodiphenylsulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Microbiol. Lett., 177, 231-235.
20. Williams, D.L., Spring, L., Harris, E., et al. (2000): Dihydropterote synthase of Mycobacterium leprae and dapsone resistance. Antimicrob. Agents Chemother., 44, 429-432.
21. Maeda, S., Matsuoka, M., Nakata, N., et al. (2001): Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob. Agents Chemother., 45, 3635-3639.
22. Williams, D.L., Pittman, T.L., Gillis, T.P., et al. (2001): Simultaneous detection of Mycobacterium leprae and its susceptibility to dapsone using DNA heteroduplex analysis. J. Clin. Microbiol., 39, 2083-2088.
23. Cambau, E., Carthagena, L., Chauffour, A., et al. (2006): Dihydropterote synthase in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin. Infect. Dis., 42, 238-241.
24. Matsuoka, M., Budiawan, T., Khin, S.A., et al. (2007): The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr. Rev., 78, 343-352.
25. Zhang, L., Namisato, M. and Matsuoka, M. (2004): A mutation at codon 516 in the rpoB gene confers resistance to rifampin. Int. J. Lepr. Other Mycobact. Dis., 72, 468-472.
26. Shepard, C.C. (1960): The experimental disease that follows the injection of human leprosy bacilli into foot-pad of mice. J. Exp. Med., 112 445-454.
27. Pettit, J.H.S. and Rees, R.J.W. (1964): Sulphone resistance in leprosy. An experimental and clinical study. Lancet, 26, 673-674.
28. Guinto, R.S., Cellona, R.V., Fajardo, T.T., Jr., et al. (1981): Primary dapsone-resistant leprosy in Cebu, Philippines. Int. J. Lepr. Other Mycobact. Dis., 41, 427-430.
29. Rees, R.J.W., Pearson, J.M.H. and Waters, M.F.R. (1970): Experimental and clinical studies on rifampicin in treatment of leprosy. Br. Med. J., 1, 89-92.
30. Shepard, C.C., Levy, L. and Fasal, P. (1972): Rapid bactericidal effect of rifampin on Mycobacterium leprae. Am. J. Trop. Med. Hyg., 21, 446-449.
31. Shepard, C.C., Levy, L. and Fasal, P. (1974): Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae. Am. J. Trop. Med. Hyg., 23, 1120-1124.
32. Levy, L., Shepard, C.C. and Fasal, P. (1976): The bactericidal effect of rifampicin on Mycobacterium leprae in man: (a) single doses of 600 mg, 900 and 1200 mg; and (b) daily doses of 300 mg. Int. J. Lepr. Other Mycobact. Dis., 44, 183-187.
33. Cambau, E., Bonnafous, P., Perani, E., et al. (2002): Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin. Infect. Dis., 34, 39-45.
34. Honoré, N., Perrani, E., Teleni, A., et al. (1993): A simple and rapid method for detection of rifampin resistance in Mycobacterium leprae. Int. J. Lepr. Other Mycobact. Dis., 61, 600-604.
35. Honoré, N. and Cole, S.T. (1993): Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob. Agents Chemother., 37, 414-417.
36. Williams, D., Waguespack, C., Eisenach, K., et al. (1994): Characterization of rifampin resistance in pathogenic mycobacteria. Antimicrob. Agents Chemother., 38, 2380-2386.
37. Musser, J. (1995): Antimicrobial agents resistance in mycobacteria: a molecular genetic insights. Clin. Microbiol. Rev., 8, 496-514.
38. Jacobson, R.R. and Hastings, R.C. (1976): Rifampin-resistant leprosy. Lancet, 2, 1304-1305.
39. Guelpa-Lauras, C.-C., Grosset, J.H., Constant-Desportes, M., et al. (1984): Nine cases of rifampicin-resistant leprosy. Int. J. Lepr. Other Mycobact. Dis., 52, 101-102.
40. Grosset, J.H., Guelpa-Lauras, C.-C., Bobin, P., et al. (1989): Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int. J. Lepr. Other Mycobact. Dis., 557, 607-614.
41. Saito, H., Tomioka, H. and Nagashima, K. (1986): In vitro and in vivo activities of ofloxacin against Mycobacterium leprae infection induced in mice. Int. J. Lepr. Other Mycobact. Dis., 54, 560-562.
42. Grosset, J.H., Ji, B., Guelpa-Lauras, C.C., et al. (1990): Clinical trial of perfloxacin and ofloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis., 58, 281-295.
43. Takiff, H.E., Salazar, L., Guerrero, C., et al. (1994): Cloning and sequencing of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutation. Antimicrob. Agents Chemother., 38, 773-780.
44. Cambau, E., Saugacoff, W., Besson, M., et al. (1994): Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J. Infect. Dis., 170, 479-483.
45. Cambau, E. and Jarlier, V. (1996): Resistance to quinolones in Mycobacteria. Res. Microbiol., 147, 52-59.
46. Morrison, N.E. and Marley, G. (1976): Clofazimine binding studies with deoxyribonucleic acid. Int. J. Lepr. Other Mycobact. Dis., 44, 475-481.
47. Browne, S.G. and Hogerzeil, L.M. (1962): "B663" in the treatment of leprosy. Preliminary report of pilot trial. Lepr. Rev., 33, 6-10.
48. Browne, S.G. and Hogerzeil, L.M. (1962): Apparent resistance of M. leprae to "B663". Lepr. Rev., 33, 185-189.
49. Diepen, T.W.-V. (1982): Clofazimine-resistant leprosy, a case report. Int. J. Lepr. Other Mycobact. Dis., 50, 139-142.
50. Shetty, V.P., Uplekar, M.W. and Antia, N.H. (1996): Primary resistance to single and multiple drugs in leprosy --- a mouse footpad study. Lepr. Rev., 67, 280-286.
51. Ebenezer, G.J., Norman, G., Joseph, G.A., et al. (2002): Drug resistant-Mycobacterium leprae --- results of mouse footpad studies from a laboratory in south India. Int. J. Lepr. Other Mycobact. Dis., 74, 301-312.
52. Gelber, R.H. (1987): Activity of mynocycline in Mycobacterium leprae infected mice. J. Infect. Dis., 186, 236-239.
53. Gelber, R.H. and Rea, T.H. (1991): Minocycline has impressive activity against lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis., 59, 193-194.
54. Ji, B., Perani, E.G. and Grosset, J.H. (1991): Effectiveness of clarithromycin and miocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob. Agents Chemother., 35, 579-581.
55. Taylor, D.E. and Chau, A. (1996): Tetracycline resistance mediated by ribosomal protection: mini review. Antimicrob. Agents Chemother., 40, 1-5.
56. Nakajima, H., Nagao, E., Ozaki, M., et al. (1997): Diagnosis of Hansen's disease. Guideline for the treatment. Ministry of Health and Welfare, Tofu Kyokai (in Japanese).
57. Goto, M., Ishida, Y., Gidoh, M., et al. (2000): Guideline for the treatment of Hansen's disease in Japan. Jpn. J. Lepr., 69, 157-177 (in Japanese).
58. Ji, B. (1987): Drug susceptibility testing of Mycobacterium leprae. Int. J. Lepr. Other Mycobact. Dis., 55, 830-835.
59. Shepard, C.C., Rees, R.J., Levy, L., et al. (1986): Susceptibility of strains of Mycobacterium leprae isolated prior to 1977 from patients with previously untreated lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis., 54, 11-15.
60. Rees, R.J. (1967): Drug resistance of Mycobacterium leprae particularly to DDS. Int. J. Lepr. Other Mycobact. Dis., 35, 625-636.
61. Peason, J.M.H., Cap, J.A. and Haile, G.S. (1977): Dapsone-resistant leprosy and implications for leprosy control programmes. Lepr. Rev., 48, 83-84.
62. Matsuoka, M., Khin, S.A., Kyaw, K., et al. (2008): A novel method for simple detection of mutations conferring drug resistance in Mycobacterium leprae, based on a DNA microarray, and its applicability in developing countries. J. Med. Microbiol., 57, 1213-1219.
63. World Health Organization (2009): Guidelines for Global Surveillance of Drug Resistance in Leprosy. SEA-GLP 2009.2.